NEWS
Targeted Drug for Melanoma Shows Promise in Early Clinical Testing
The vast majority of patients with advanced melanoma who received an experimental targeted drug called PLX4032 responded to the treatment in a phase I clinical trial, researchers announced last month. The drug targets a common genetic change in melanoma tumors, and 26 of 32 patients (81 percent) who were treated with the recommended phase II dose had a partial or complete response. The tumors of some patients shrank or even went away, at least temporarily. Read more > >
For Women with BRCA Mutations, Prophylactic Surgery Reduces Cancer Risk
Results are from one of the largest prospective studies on this subject to dateLess-intensive Treatment Regimen Effective against Multiple Myeloma
Changing the dosage of bortezomib reduced side effects but not efficacyLower-dose Treatments for Early-stage Hodgkin Lymphoma Do Not Compromise Results
Researchers seek ways to reduce treatment-associated adverse eventsChemotherapy Affects Brain Structure of Breast Cancer Patients
MRI scans show changes in gray matter following chemotherapyConsuming High Levels of Red Meat and Fat May Increase Liver Cancer Risk
Eating white meat was associated with reduced riskCancer Patients Leaving Hospice Early Boost Medicare Expenditures
Understanding why patients disenroll may reduce end-of-life care expenses
COMMENTARY
Inside NCI: A Conversation with Dr. Crystal Mackall about Pediatric Oncology 
The chief of NCI’s Pediatric Oncology Branch talks about the research in her lab at NCI and areas where pediatric cancer researchers are poised to make major advances. Read more > >
A MESSAGE TO READERS
Bulletin Survey to Launch September 14
Readers who subscribe to the NCI Cancer Bulletin will receive an e-mail message next Tuesday with a hyperlinked invitation to participate in our biannual survey. The survey is a tool we use to learn about what you like the most about our newsletter and what we can change to better suit your needs. The survey will be active for 3 weeks, so don’t miss your chance to participate.
IN DEPTH
Palliative Care Improves Survival, Quality of Life in Advanced Lung Cancer
Trial raises hopes that results may alter perception, if not use of palliative care
Autophagy: The Strange Dining Habits of Cancer Cells
Some cancer cells’ penchant for self-cannibalism may present a new therapeutic opportunity
Featured Clinical Trial: Comparing Post-transplant Therapies for Multiple Myeloma Patients
What is the best course of treatment following autologous stem cell transplantation?
UPDATES
Notes
- NCAB Meeting Begins Today
- New Grants Awarded for Biomarker Discovery and Validation
- Federal Committee Will Establish Breast Cancer Research Agenda
- Glasgow Named DCCPS Deputy Director
- Groundbreaking Ceremony Held for NCI’s Future Satellite Campus
- New Brochure on Cancer Genomics Available
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
